🇺🇸 FDA
Patent

US 12291507

Compounds and their use for the treatment of ALPHA1-antitrypsin deficiency

granted A61PA61P11/00

Quick answer

US patent 12291507 (Compounds and their use for the treatment of ALPHA1-antitrypsin deficiency) held by CENTESSA PHARMACEUTICALS (UK) LIMITED expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
CENTESSA PHARMACEUTICALS (UK) LIMITED
Grant date
Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61P, A61P11/00